Literature DB >> 33842256

The expression and clinical significance of signal transducer and activator of transcription 3, tumor necrosis factor α induced protein 8-like 2, and runt-related transcription factor 1 in breast cancer patients.

Daitian Lan1,2, Xuchu Jin2,3, Maode Li1,2, Li He2,3.   

Abstract

BACKGROUND: This study explored the expression and clinical significance of signal transducer and activator of transcription 3 (STAT3), tumor necrosis factor α induced protein 8-like 2 (TIPE2), and runt-related transcription factor 1 (RUNX1) in breast cancer tissue.
METHODS: From October 2014 to October 2017, 68 breast cancer patients (68 breast cancer tissue specimens) who underwent a radical mastectomy in our hospital were set as the observation group and the corresponding normal tissue 3 cm away from the cancer tissue was selected as the control group. The expression levels of STAT3, TIPE2, and RUNX1 in the two groups were compared via immunohistochemical staining. Multiple logistic regression was then used to analyze the related risk factors affecting the 2-year prognosis of breast cancer patients. The receiver operating characteristic (ROC) curve was then plotted and the area under the ROC curve was calculated. The predictive values of STAT3, TIPE2, and RUNX1, and the predictive value of the three transcription factors combined on the 2-year prognostic survival of breast cancer patients were determined.
RESULTS: (I) In the observation group, the positive expression of STAT3 and the negative expression of TIPE2 and RUNX1 were significantly higher than those in the control group (P<0.05). (II) Of the 68 patients, 51 survived within 2 years and 17 patients died. Positive STAT3 expression, negative TIPE2 expression, negative RUNX1 expression, poor histological differentiation, TNM stage III-IV, and distant metastasis were all identified as factors that can affect the 2-year prognosis of breast cancer patients (P<0.05). (III) The ROC curve analysis examining the 2-year prognostic survival of breast cancer patients showed that the area under the curve achieved the largest value when the predictive values of STAT3, TIPE2, RUNX1 were combined.
CONCLUSIONS: The levels of STAT3, TIPE2, and RUNX1 expression in breast cancer tissues were significantly different from that in adjacent normal tissues. This suggested that the combined detection of STAT3, TIPE2, and RUNX1 may improve the rate of early breast cancer diagnosis. Furthermore, STAT3, TIPE2, and RUNX1 may be useful in evaluating the prognosis of the patients with breast cancer. 2021 Gland Surgery. All rights reserved.

Entities:  

Keywords:  Signal transducer and activator of transcription 3 (STAT3); breast cancer; runt-related transcription factor 1 (RUNX1); tumor necrosis factor α induced protein 8-like 2 (TIPE2)

Year:  2021        PMID: 33842256      PMCID: PMC8033044          DOI: 10.21037/gs-21-108

Source DB:  PubMed          Journal:  Gland Surg        ISSN: 2227-684X


  27 in total

Review 1.  The benefits and harms of breast cancer screening: an independent review.

Authors:  M G Marmot; D G Altman; D A Cameron; J A Dewar; S G Thompson; M Wilcox
Journal:  Br J Cancer       Date:  2013-06-06       Impact factor: 7.640

2.  Gene delivery of TIPE2 inhibits breast cancer development and metastasis via CD8+ T and NK cell-mediated antitumor responses.

Authors:  Zhenhua Zhang; Li Liu; Shousong Cao; Yizhun Zhu; Qibing Mei
Journal:  Mol Immunol       Date:  2017-03-15       Impact factor: 4.407

3.  MiR-124 reversed the doxorubicin resistance of breast cancer stem cells through STAT3/HIF-1 signaling pathways.

Authors:  Cong Liu; Hua Xing; Caixia Guo; Zhaoying Yang; Yimin Wang; Yingying Wang
Journal:  Cell Cycle       Date:  2019-07-29       Impact factor: 4.534

4.  Musashi RNA-binding protein 2 regulates estrogen receptor 1 function in breast cancer.

Authors:  M-H Kang; K J Jeong; W Y Kim; H J Lee; G Gong; N Suh; B Győrffy; S Kim; S-Y Jeong; G B Mills; Y-Y Park
Journal:  Oncogene       Date:  2016-09-05       Impact factor: 9.867

5.  MicroRNA-378-mediated suppression of Runx1 alleviates the aggressive phenotype of triple-negative MDA-MB-231 human breast cancer cells.

Authors:  Gillian Browne; Julie A Dragon; Deli Hong; Terri L Messier; Jonathan A R Gordon; Nicholas H Farina; Joseph R Boyd; Jennifer J VanOudenhove; Andrew W Perez; Sayyed K Zaidi; Janet L Stein; Gary S Stein; Jane B Lian
Journal:  Tumour Biol       Date:  2016-01-09

6.  Quantitative [18F]FMISO PET Imaging Shows Reduction of Hypoxia Following Trastuzumab in a Murine Model of HER2+ Breast Cancer.

Authors:  Anna G Sorace; Anum K Syed; Stephanie L Barnes; C Chad Quarles; Violeta Sanchez; Hakmook Kang; Thomas E Yankeelov
Journal:  Mol Imaging Biol       Date:  2017-02       Impact factor: 3.488

7.  Partners of young breast cancer survivors: a cross-sectional evaluation of psychosocial concerns, coping, and mental health.

Authors:  Nancy A Borstelmann; Shoshana Rosenberg; Shari Gelber; Yue Zheng; Meghan Meyer; Kathryn J Ruddy; Lidia Schapira; Steven Come; Virginia Borges; Tamara Cadet; Peter Maramaldi; Ann H Partridge
Journal:  J Psychosoc Oncol       Date:  2020-10-01

8.  Runt-Related Transcription Factor 2 Induction During Differentiation of Wharton's Jelly Mesenchymal Stem Cells to Osteoblasts Is Regulated by Jumonji AT-Rich Interactive Domain 1B Histone Demethylase.

Authors:  Francisco Bustos; Hugo Sepúlveda; Catalina P Prieto; Margarita Carrasco; Lorena Díaz; José Palma; José Lattus; Martín Montecino; Verónica Palma
Journal:  Stem Cells       Date:  2017-09-29       Impact factor: 6.277

9.  Bone morphogenetic protein 9 (BMP9) and BMP10 enhance tumor necrosis factor-α-induced monocyte recruitment to the vascular endothelium mainly via activin receptor-like kinase 2.

Authors:  Claudia-Gabriela Mitrofan; Sarah L Appleby; Gerard B Nash; Ziad Mallat; Edwin R Chilvers; Paul D Upton; Nicholas W Morrell
Journal:  J Biol Chem       Date:  2017-06-23       Impact factor: 5.157

10.  Inhibition of Stat3 Signaling Pathway by Natural Product Pectolinarigenin Attenuates Breast Cancer Metastasis.

Authors:  Yali Li; Cailing Gan; Yange Zhang; Yan Yu; Chen Fan; Yuanle Deng; Qianyu Zhang; Xi Yu; Yiwen Zhang; Liqun Wang; Fang He; Yongmei Xie; Tinghong Ye; Wenya Yin
Journal:  Front Pharmacol       Date:  2019-10-10       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.